Target and Its Patented Drug(s)

Content Navigation (  All   None )                                      
Target General Information
Patent(s) and the Corresponding Patented Drug(s)
References
Target General Information  Top
Target ID T46465 Target Info
Target Name Plasmodium Plasmepsin 2 (Malaria PLA2)
Synonyms Plasmepsin-2; PFAPD; Aspartic hemoglobinase II
Target Type Patented-recorded Target
Gene Name Malaria PLA2
Biochemical Class Peptidase
UniProt ID
PLM2_PLAFA
Patent(s) and the Corresponding Patented Drug(s)  Top
United States Patent and Trademark Office (USPTO)
Patent ID US9353089
Title Compositions and methods for the treatment of malaria
Abstract The present invention provides aminohydantoin anti-malarial agents. In some embodiments, these agents have the property of functions of targeting malarial aspartic proteases while at the same time having low activity against human BACE. Methods of employing such agents are also provided.
Applicant(s) Saint Louis University; Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences
Representative Drug(s) D0QX1S Drug Info IC50 = 240 nM Click to Show More [1]
2 D0H4IY Drug Info IC50 = 751 nM [1]
3 D03OLC Drug Info IC50 = 1010 nM [1]
Patent ID US9353089
Title Compositions and methods for the treatment of malaria
Abstract The present invention provides aminohydantoin anti-malarial agents. In some embodiments, these agents have the property of functions of targeting malarial aspartic proteases while at the same time having low activity against human BACE. Methods of employing such agents are also provided.
Applicant(s) Saint Louis University; Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences
Representative Drug(s) D0QX1S Drug Info IC50 = 240 nM Click to Show More [1]
2 D0H4IY Drug Info IC50 = 751 nM [1]
3 D03OLC Drug Info IC50 = 1010 nM [1]
Patent ID US9353089
Title Compositions and methods for the treatment of malaria
Abstract The present invention provides aminohydantoin anti-malarial agents. In some embodiments, these agents have the property of functions of targeting malarial aspartic proteases while at the same time having low activity against human BACE. Methods of employing such agents are also provided.
Applicant(s) Saint Louis University; Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences
Representative Drug(s) D0QX1S Drug Info IC50 = 240 nM Click to Show More [1]
2 D0H4IY Drug Info IC50 = 751 nM [1]
3 D03OLC Drug Info IC50 = 1010 nM [1]
References  Top
REF 1 Compositions and methods for the treatment of malaria. US9353089.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.